Parallax Volatility Advisers
SMMT icon

Parallax Volatility Advisers’s Summit Therapeutics SMMT Stock Holding History

Parallax Volatility Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,547
Closed -$111K – 2080
2024
Q4 		$99K Buy
+5,547
New +$108K ﹤0.01% 1742

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Parallax Volatility Advisers's SMMT Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 5,547 shares — an estimated $111K sold.

Parallax Volatility Advisers first reported a position in SMMT in Q4 2024 and held it in 1 quarter. The position peaked at $99K in Q4 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

  • Parallax Volatility Advisers reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,547 Summit Therapeutics shares in Q1 2025, an estimated $111K.
  • Parallax Volatility Advisers first reported a position in Summit Therapeutics in Q4 2024 and held it in 1 quarter.
  • Parallax Volatility Advisers's Summit Therapeutics position peaked at $99K in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.